Aldeyra Therapeutics (ALDX) Q4 2025 earnings summary

Executive summary

• Focused on developing therapies for immune-mediated diseases, with late-stage candidates reproxalap (for dry eye disease and allergic conjunctivitis) and ADX-2191 (for primary vitreoretinal lymphoma and retinitis pigmentosa).

• No products approved for sale as of December 31, 2025; revenue generation depends on regulatory approvals and successful commercialization.

• Entered an exclusive option agreement with AbbVie for reproxalap, with potential for significant milestone and royalty payments.

Financial highlights

• Net loss for 2025 was $33.8 million, a decrease from $55.9 million in 2024.

• Research and development expenses were $25.7 million in 2025, down from $48.2 million in 2024, primarily due to lower clinical and manufacturing costs.

• General and administrative expenses were $9.6 million in 2025, down from $11.9 million in 2024.

• Cash and cash equivalents totaled $70.0 million at year-end 2025.

• Stockholders’ equity was $44.3 million as of December 31, 2025.

Outlook and guidance

• Cash and cash equivalents expected to fund operations for at least twelve months from February 27, 2026.

• Additional capital will be needed for continued development and commercialization activities.

• Awaiting FDA decision on reproxalap NDA resubmission, with a PDUFA date extended to March 16, 2026.